Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
VCYT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.61 - $47.32
Previous CloseN/A
Volume253.49K
Average Volume (3M)932.49K
Market Cap
$2.69B
Enterprise Value$2.42B
Total Cash (Recent Filing)$78.00M
Total Debt (Recent Filing)$25.28M
Price to Earnings (P/E)113.4
Beta2.25
Next Earnings
May 13, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.31
Shares Outstanding77,499,626
10 Day Avg. Volume1,184,284
30 Day Avg. Volume932,486
Standard Deviation0.16
R-Squared0.30
Alpha0.00093
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.33
Price to Cash Flow (P/CF)22.50
P/FCF Ratio24.30
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.74
Enterprise Value/Ebitda180.08
Forecast
1Y Price Target
$48.75Price Target Upside45.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Veracyte News
PremiumCompany Announcements
Veracyte Inc. Reports Strong 2024 Earnings Amid Challenges
PremiumCompany Announcements
Veracyte Inc. Reports Strong 2024 Financial Performance---
Bulls Say, Bears Say
Bulls Say
Market ShareDecipher has over 65% market share and has driven clinician awareness and adoption with orders increasing across both new and existing accounts.
Revenue PerformanceFourth-quarter revenue was 2% ahead of consensus, with Decipher revenue growing 44% and AEBITDA margins of 22% further differentiating Veracyte from other diagnostics peers.
Bears Say
French Subsidiary ExitShares were called down roughly 7% in post-market trading, likely on some questions over the French subsidiary exit.
---
Ownership Overview
1.22% Insiders
33.48% Mutual Funds
31.50% Other Institutional Investors
8.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $18.61 and its highest was $47.32 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $2.69B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is May 13, 2025 which is in 70 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Feb 24, 2025. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.113 by -$0.053.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.05.
How many shares outstanding does Veracyte have?
Veracyte has 77,499,626 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.06 in its last earnings report, missing expectations of $0.113. Following the earnings report the stock price went down -14.99%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
---
Veracyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.75 (45.26% Upside)
$48.75 (45.26% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 68.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $549.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.23%
12-Months-Change
Fundamentals
Return on Equity
2.17%
Trailing 12-Months
Asset Growth
17.24%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
---
VCYT Company Deck
---
VCYT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in revenue growth and market penetration, particularly with the Decipher test. However, there are notable challenges, including a decline in product revenue and potential operational changes in the French subsidiary that could impact future performance and product availability.Read More>---
VCYT Stock 12 Month Forecast
Average Price Target
$48.75
▲(45.26% Upside)
Technical Analysis
Best Analysts Covering VCYT
1 Year
1 Year Success Rate
15/21 ratings generated profit
1 Year Average Return
+47.85%
reiterated a buy rating 15 hours ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +47.85% per trade.
---